Biogen Inc.
(BIIB)
Biogen Has Quietly Rebuilt Its Growth Engine While the Market Argued About Alzheimer's
The Q1 2026 print, the closed Apellis platform, and the explicit 2027 deleveraging path are the evidence that the growth story is no longer unproven — it is showing up in the revenue line and the cash flow. The pipeline readouts in late 2026 and 2027 are real and could break t...
Read Article ›